Are you considering semaglutide for managing your diabetes
LLMs mapped patient language to medical terminology at a scale that wasn't possible before
Of note, in the SURPASS-4 trial, adjudicated major adverse cardiovascular events (MACE) were not increased with tirzepatide compared with insulin glargine over an extended follow-up period of 52 additional weeks after the main trial period of 52 weeks [21]
Oxytocin sold on marketplaces is often unregulated and may not contain pharmaceutical-grade ingredients
Research has shown that: Weight regain often occurs if semaglutide is discontinued, with most patients regaining two-thirds of their lost weight within a year Long-term use may be necessary for maintaining weight loss, similar to treatments for other chronic conditions Regular monitoring by healthcare providers helps identify and address any concerns Five-year safety data now becoming available continues to support the medications favorable risk-benefit profile The FDA continues post-marketing surveillance of semaglutide to identify any rare adverse events that might not have been detected in clinical trials
The data mean the drug met the study goal of showing non-inferiority that is, Mounjaro did not perform worse than Trulicity, but the result was not statistically significant, meaning Mounjaro was not proven to be better than Trulicity
